Familial hypocalciuric hypercalcemia as a differential diagnosis of primary hyperparathyroidism with negative images
Abstract
Introduction. Familial hypocalciuric hypercalcemia is a rare inherited calcium metabolism disorder in which an alteration of the parathyroid hormone secretion set-point causes hypercalcemia with relative hypocalciuria. Some data suggest that its prevalence is around 74.1 per 100,000 inhabitants. Often, patients are asymptomatic. However, they can develop mild symptoms and an overactive parathyroid adenoma, its main differential diagnosis. The objective was to describe a patient’s case and highlight the importance of clinical suspicion and diagnosis to avoid unnecessary surgical neck explorations for parathyroid adenomas. Case report. This is the case of a 40-year-old man with a biochemical profile compatible with primary hyperparathyroidism with anatomical and functional images negative for adenoma and a calcium/creatinine clearance ratio below 0.001, considering familial hypocalciuric hypercalcemia. Genetic studies evidence a mutation in the calcium sensor receptor gene and confirm the diagnosis. Discussion. Familial hypocalciuric hypercalcemia’s main differential diagnosis is an overactive parathyroid adenoma. For both, mild or no symptoms may be present; serum calcium exceeds the upper limit, and parathormone is more than 25pg/ml. The calcium/creatinine clearance ratio should be used to differentiate one from the other and avoid unnecessary surgical neck explorations. Besides the lack of information on this topic, evidence supports the use of calcimimetics to treat symptomatic hypercalcemia. Conclusions. Patients with mild hypercalcemia with parathyroid hormone readings above 25pg/ml and a calcium/creatinine clearance ratio below 0.001, or patients with primary hyperparathyroidism with negative imaging, should not undergo surgical neck explorations. In these cases, familial hypocalciuric hypercalcemia is a reliable diagnosis; Cinacalcet may be administered in cases of symptomatic hypercalcemia.
References
Lee JY, Shoback DM. Familial hypocalciuric hypercalcemia and related disorders. Best Pract Res Clin Endocrinol Metab [Internet]. 2018;32(5):609-619. doi: https://doi.org/10.1016/j.beem.2018.05.004
D'Souza-Li L, Yang B, Canaff L, Bai M, Hanley DA, Bastepe M, et al. Identification and Functional Characterization of Novel Calcium-Sensing Receptor Mutations in Familial Hypocalciuric Hypercalcemia and Autosomal Dominant Hypocalcemia. J Clin Endocrinol Metab [Internet]. 2002;87(3):1309-18. doi: https://doi.org/10.1210/jcem.87.3.8280
Builes-Montaño CE. Hiperparatiroidismo primario. Med. Lab [Internet]. 2017;23(1-2):45-4. doi: https://doi.org/10.36384/01232576.59
Dershem R, Gorvin CM, Metpally RPR, Krishnamurthy S, Smelser DT, Hannan FM, et al. Familial Hypocalciuric Hypercalcemia Type 1 and Autosomal-Dominant Hypocalcemia Type 1: Prevalence in a Large Healthcare Population. Am J Hum Genet [Internet]. 2020;106(6):734–47. doi: https://doi.org/10.1016/j.ajhg.2020.04.006
Mahajan A, Buse J, Kline G. Parathyroid hormone-dependent familial hypercalcemia with low measured PTH levels and a presumptive novel pathogenic mutation in CaSR. Osteoporos Int [Internet]. 2020;31:203–7. doi: https://doi.org/10.1007/s00198-019-05170-9
Brown EM. Clinical lessons from the calcium-sensing receptor. Nat Rev Endocrinol [Internet]. 2007;3:122–133. doi: https://doi.org/10.1038/ncpendmet0388
Merino M, Vega B, Guijarro G, Navea C, Torán C, Civantos S. Familial hypocalciuric hypercalcemia: sometimes it is not what it seems. Rev Osteoporos Metab Miner [Internet]. 2015;7(1):20-22. doi: https://doi.org/10.4321/S1889-836X2015000100005
Renaghan AD, Rosner MH. Hypercalcemia: etiology and management. Nephrol Dial Transplant [Internet]. 2018;33(4):549-551. doi: https://doi.org/10.1093/ndt/gfy054
Silva BC, Cusano NE, Bilezikian JP. Primary hyperparathyroidism. Best Pract Res Clin Endocrinol Metab [Internet]. 2018;32(5):593-607. doi: https://doi.org/10.1016/j.beem.2018.09.004
Fuleihan GEH, Silverberg SJ. Primary hyperparathyroidism: Diagnosis, differential diagnosis, and evaluation. Post TW, ed. Waltham, MA: UpToDate Inc [Internet]. 2020. Available from: https://www.uptodate.com/contents/primary-hyperparathyroidism-diagnosis-differential-diagnosis-and-evaluation?search=primary%20hyperparathyroidism&source=search_result&selectedTitle=1~119&usage_type=default&display_rank=1
Pulgar D, Jans J, D'Aguzan N, León A, Goñi I, González G, et al. Hiperparatiroidismo primario: manejo quirúrgico. Rev Chil Cir [Internet]. 2014;66(4):313-319. doi: https://doi.org/10.4067/S0718-40262014000400004
Bilezikian JP. Primary Hyperparathyroidism. J Clin Endocrinol Metab [Internet]. 2018;103(11):3993–4004. doi: https://doi.org/10.1210/jc.2018-01225
Marx SJ. Calcimimetic Use in Familial Hypocalciuric Hypercalcemia—A Perspective in Endocrinology. J Clin Endocrinol Metab [Internet]. 2017;102(11):3933-3936. doi: https://doi.org/10.1210/jc.2017-01606
Scheers I, Sokal E, Limaye N, Denoncin C, Stephenne X, Pirson Y, et al. Cinacalcet sustainedly prevents pancreatitis in a child with a compound heterozygous SPINK1/AP2S1 mutation. Pancreatology [Internet]. 2019;19(6):801-804. doi: https://doi.org/10.1016/j.pan.2019.07.045
Mayr B, Schnabel D, Dörr HG, Schöfl C. GENETICS IN ENDOCRINOLOGY: Gain and loss of function mutations of the calcium-sensing receptor and associated proteins: current treatment concepts. Eur J Endocrinol [Internet]. 2016;174(5):R189-R208. doi: https://doi.org/10.1530/EJE-15-1028
Rasmussen AQ, Jørgensen NR, Schwarz P. Clinical and biochemical outcomes of cinacalcet treatment of familial hypocalciuric hypercalcemia: a case series. J Med Case Rep [Internet]. 2011;5:564. doi: https://doi.org/10.1186/1752-1947-5-564
Downloads
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
